Premium
Tacrolimus enhances irritation in a 5‐day human irritancy in vivo model
Author(s) -
Fuchs M.,
SchliemannWillers S.,
Heinemann C.,
Elsner P.
Publication year - 2002
Publication title -
contact dermatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.524
H-Index - 96
eISSN - 1600-0536
pISSN - 0105-1873
DOI - 10.1034/j.1600-0536.2002.460508.x
Subject(s) - irritation , erythema , irritant contact dermatitis , dermatology , transepidermal water loss , contact dermatitis , allergic contact dermatitis , medicine , allergy , tacrolimus , patch test , atopic dermatitis , skin irritation , surgery , immunology , pathology , transplantation , stratum corneum
Tacrolimus (FK 506) is a macrolide discovered in 1984 as a metabolic product of Streptomyces tsukabaensis . It has been used successfully in treating atopic dermatitis, allergic contact dermatitis, lichen planus mucosae and pyoderma gangrenosum. In the present study, we evaluated the anti‐inflammatory activity of FK 506 in 2 human skin inflammation models. FK 506 as Protopic ® cream was tested (i) in a 4‐day repetitive irritation test with 2 × daily application of sodium lauryl sulphate (SLS), and (ii) in a UVB erythema model. The effect was evaluated visually and quantified by non‐invasive bioengineering methods, namely chromametry and tewametry (TEWL). When FK 506 was applied 30 min after SLS irritation, an increased inflammation in comparison to controls was observed with all 3 methods, with only the TEWL data reaching statistical significance. 1 × daily application of FK 506 for 5 days, starting at the end of the 4‐day irritation period, was without any effect. Similarly, no effect of FK 506 was seen in the UVB model. In conclusion, FK 506 was shown to enhance experimentally induced irritant contact dermatitis and not to accelerate healing of irritant contact dermatitis and UVB erythema.